Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice

• Published in: Probiotics and antimicrobial proteins 2022-06, Vol.14 (3), p.486-500
• Main Authors: Coutinho, Joana O. P. A., Quintanilha, Mônica F., Campos, Marina R. A., Ferreira, Enio, de Menezes, Graciéle C. A., Rosa, Luiz H., Rosa, Carlos A., Vital, Katia D., Fernandes, Simone O. A., Cardoso, Valbert N., Nicoli, Jacques R., Tiago, Fabiana C. P., Martins, Flaviano S.
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Animals; Antarctic Regions; Applied Microbiology; Body weight; Body weight loss; Chemistry; Chemistry and Materials Science; Chemistry/Food Science; Chemotherapy; Feces; Fluorouracil - adverse effects; Food consumption; Food intake; Humans; Ileum; Inflammation; Intestinal Mucosa; Intestine; Jejunum; Mice; Microbiology; Mucositis; Mucositis - chemically induced; Mucositis - drug therapy; Mucositis - prevention & control; Nutrition; Oral administration; Permeability; Probiotics; Protein Science; Rhodotorula; Rhodotorula mucilaginosa; Side effects
• ISSN: 1867-1306; 1867-1314
• DOI: 10.1007/s12602-021-09817-0

Mucositis is one of the most strenuous side effects caused by chemotherapy drugs, such as 5-fluorouracil (5-FU), during the treatment of several types of cancers. The disease is so prevalent and aggressive that many patients cannot resist such symptoms. However, despite its frequency and clinical significance, there is no effective treatment to prevent or treat mucositis. Thus, the use of probiotics as an adjuvant for the treatment has gained prominence. In the present study, we evaluated the effectiveness of oral administration of the Antarctic strain of Rhodotorula mucilaginosa UFMGCB 18,377 as an alternative to minimize side effects of 5-FU-induced mucositis in mice. Body weight, food consumption, stool consistency, and presence of blood in the feces were assessed daily in mice orally treated or not with the yeast and submitted or not to experimental mucositis. Blood, bones, and intestinal tissues and fluid were used to determine intestinal permeability and immunological, microbiological, and histopathological parameters. Treatment with R. mucilaginosa UFMGCB 18,377 was able to decrease clinical signs of the disease, such as reduction of food intake and body weight loss, and also decreased the number of intestinal enterobacteria and intestinal length shortening. Additionally, treatment was able to decrease the levels of MPO and EPO activities and inflammatory infiltrates, as well as the histopathological lesions characteristic of mucositis in the jejunum and ileum. Results of the present study showed that the oral administration of R. mucilaginosa UFMGCB 18,377 protected mice against mucositis induced by 5-FU.